# Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer

> **NCT06547736** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 160 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** SHR-A2102 or/and HRS-4642
- **DRUG:** SHR-A1904 or/and HRS-4642
- **DRUG:** SHR-A1811 or/and HRS-4642
- **DRUG:** SHR-A2102, HRS4642 and Adebrelimab

## Key facts

- **NCT ID:** NCT06547736
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-14
- **Primary completion:** 2027-03
- **Final completion:** 2027-06
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-01-05

## Collaborators

- Jiangsu HengRui Medicine Co., Ltd.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06547736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06547736, "Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06547736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*